Cantor Fitzgerald Maintains Overweight Rating on Disc Medicine
Cantor Fitzgerald maintained its Overweight rating on Disc Medicine and a $170 price target. The target implies 199.1% upside from the Oct. 16 close of $56.84.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.